Compare Infosys Limited (INFY) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Revvity Inc — how do they compare? Infosys Limited trades at $12.6 (market cap $50.55B), while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Infosys Limited is far larger — about 3.9× Revvity Inc's market cap, and Infosys Limited pays the higher dividend (4.16%). Which is the better fit depends on your goals.
| INFY | RVTY | |
|---|---|---|
Market Cap | $50.55B | $12.91B |
Sector | Technology | Technology |
52-Week High | $20.22 | $117.75 |
52-Week Low | $10.49 | $82.26 |
Enterprise Value | $48.30B | $15.23B |
Dividend Yield | 4.16% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $12.28, down 2.23% today, with a mixed technical picture showing bullish moving averages but overbought RSI levels. Fundamentally, the company reported Q1 2027 revenue below expectations but maintained strong margins and AI growth, with a P/E of 15.56 and robust ROE of 32.12%. Recent news includes strategic AI collaborations and a CEO transition, while analyst sentiment remains cautious with a consensus price target of $11.05.
The outlook for INFY is balanced; solid profitability and AI adoption offer upside, but near-term revenue softness and elevated valuation pose risks. Investors should weigh strong cash flow and market position against competitive pressures and execution challenges in a volatile IT services market.
RVTY trades at $117.88, up 1.6% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock is near the consensus price target of $120.50, supported by a 51.72% analyst buy rating. Recent news highlights product launches like the SuperFlex prenatal system and investor conference participation, reinforcing growth prospects in diagnostics and biotech tools.
The outlook remains positive with revenue stability and margin strength, but elevated P/E of 55.64 poses valuation risk. Key opportunities include diagnostic demand and AI-driven workflows, while risks involve competitive pressures and execution challenges. Net cash flow turned positive in 2026, signaling improved financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
